Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer”

2 trials

Showing 2 of 2 results

Testing effectiveness (Phase 2)Looking for participantsNCT05749900
What this trial is testing

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Who this might be right for
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University 44
Testing effectiveness (Phase 2)Study completedNCT04722133
What this trial is testing

Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

Who this might be right for
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University 36

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation